[{"id":"76342840-6206-4b74-a0cb-9378bde5b3a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469891","created_at":"2026-03-28T01:43:33.576Z","updated_at":"2026-03-28T01:43:33.576Z","phase":"Phase 1","brief_title":"A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms","source_id_and_acronym":"NCT07469891","lead_sponsor":"Prelude Therapeutics","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2026-03-13"},{"id":"a688087c-68be-4853-9780-49620057e35d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04517851","created_at":"2021-01-18T21:38:49.784Z","updated_at":"2025-02-25T15:26:29.899Z","phase":"Phase 2","brief_title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","source_id_and_acronym":"NCT04517851","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • IL1R1 • SLAMF7","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • IL1R1 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2021","start_date":" 02/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-10"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"1f02bb00-f1cc-41ae-861d-71bd39144975","acronym":"VYP","url":"https://clinicaltrials.gov/study/NCT06715267","created_at":"2025-02-26T10:35:18.326Z","updated_at":"2025-02-26T10:35:18.326Z","phase":"","brief_title":"Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)","source_id_and_acronym":"NCT06715267 - VYP","lead_sponsor":"University Hospital, Brest","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2038","primary_completion_date":" 04/01/2038","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-12-04"},{"id":"cc779273-45ab-45c8-b571-03dd1632ce79","acronym":"GLB-001-02","url":"https://clinicaltrials.gov/study/NCT06378437","created_at":"2024-04-22T23:49:35.454Z","updated_at":"2024-07-02T16:34:59.114Z","phase":"Phase 1","brief_title":"A Study of GLB-001 in Patients With Myeloid Malignancies","source_id_and_acronym":"NCT06378437 - GLB-001-02","lead_sponsor":"Hangzhou GluBio Pharmaceutical Co., Ltd.","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 05/24/2024","start_date":" 05/24/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-04"},{"id":"7bc6ad53-4099-4558-b378-de14c0987660","acronym":"AIRPORT-MPN","url":"https://clinicaltrials.gov/study/NCT04243122","created_at":"2021-01-18T20:37:43.640Z","updated_at":"2024-07-02T16:35:00.279Z","phase":"Phase 2","brief_title":"Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients","source_id_and_acronym":"NCT04243122 - AIRPORT-MPN","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 05/03/2024","study_completion_date":" 05/03/2024","last_update_posted":"2024-05-29"},{"id":"9259cd2b-7d10-4e29-a71a-448de9ccec7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257138","created_at":"2021-01-18T10:36:04.617Z","updated_at":"2024-07-02T16:35:05.273Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","source_id_and_acronym":"NCT02257138","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jakafi (ruxolitinib) • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2024-05-08"},{"id":"8873703a-abd3-465c-96d4-165ce40e19a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04226950","created_at":"2021-01-18T20:33:33.025Z","updated_at":"2024-07-02T16:35:07.209Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","source_id_and_acronym":"NCT04226950","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 11/20/2024","study_completion_date":" 11/20/2024","last_update_posted":"2024-04-29"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"e3084173-3132-4e56-b647-4f08a948793b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01761968","created_at":"2024-03-29T16:38:22.645Z","updated_at":"2024-07-02T16:35:12.297Z","phase":"Phase 2","brief_title":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01761968","lead_sponsor":"Italfarmaco","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Duvyzat (givinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-29"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"3256127a-0abe-4b2e-b192-b4bbda0ec654","acronym":"","url":"https://clinicaltrials.gov/study/NCT01594723","created_at":"2021-01-18T06:48:50.034Z","updated_at":"2024-07-02T16:35:13.492Z","phase":"Phase 2","brief_title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01594723","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2012","start_date":" 05/22/2012","primary_txt":" Primary completion: 03/20/2015","primary_completion_date":" 03/20/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-21"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"90110e24-bfa4-4db8-9648-21c39c5dba73","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644211","created_at":"2021-01-19T20:39:16.893Z","updated_at":"2024-07-02T16:35:15.610Z","phase":"Phase 2","brief_title":"Ruxolitinib in Thrombocythemia and Polycythemia Vera","source_id_and_acronym":"NCT04644211","lead_sponsor":"Massachusetts General Hospital","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-08"},{"id":"04c90704-8700-4d3e-a27e-a296905600ec","acronym":"RELAX","url":"https://clinicaltrials.gov/study/NCT04330820","created_at":"2024-02-28T20:31:08.640Z","updated_at":"2024-07-02T16:35:17.236Z","phase":"Phase 1/2","brief_title":"Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","source_id_and_acronym":"NCT04330820 - RELAX","lead_sponsor":"Technische Universität Dresden","biomarkers":" TP53 • JAK2 • RUNX1 • PDGFRB • WT1","pipe":"","alterations":" ","tags":["TP53 • JAK2 • RUNX1 • PDGFRB • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 10/11/2023","primary_completion_date":" 10/11/2023","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-02-28"},{"id":"b4509b46-cf96-4a36-af86-5a28202e4c9b","acronym":"CONCERTO","url":"https://clinicaltrials.gov/study/NCT04409639","created_at":"2021-01-18T21:15:48.018Z","updated_at":"2024-07-02T16:35:17.291Z","phase":"Phase 2","brief_title":"Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","source_id_and_acronym":"NCT04409639 - CONCERTO","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11","pipe":" | ","alterations":" BRAF mutation • NF1 mutation","tags":["KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2026","study_completion_date":" 08/15/2026","last_update_posted":"2024-02-28"},{"id":"9ea4e22c-7e50-4995-ab97-e08e5092ac72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913026","created_at":"2021-01-18T19:15:26.504Z","updated_at":"2024-07-02T16:35:19.117Z","phase":"Phase 2","brief_title":"UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia","source_id_and_acronym":"NCT03913026","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation","tags":["TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-02-16"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"a6cd67a2-e45e-459e-9bef-bb38f433b58b","acronym":"MPL - NPM","url":"https://clinicaltrials.gov/study/NCT06246006","created_at":"2024-02-07T19:22:25.160Z","updated_at":"2024-07-02T16:35:20.317Z","phase":"","brief_title":"Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia","source_id_and_acronym":"NCT06246006 - MPL - NPM","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" JAK2 • STAT5AWqe","pipe":"","alterations":" ","tags":["JAK2 • STAT5AWqe"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-02-07"},{"id":"acb2717e-a36e-41ca-907e-430b8037d287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012230","created_at":"2021-01-18T14:49:16.634Z","updated_at":"2024-07-02T16:35:21.613Z","phase":"Phase 1","brief_title":"Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03012230","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 01/06/2023","primary_completion_date":" 01/06/2023","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2024-01-31"},{"id":"69a88472-75f1-4a2a-90e1-8b0bf04a99cd","acronym":"AALL1521","url":"https://clinicaltrials.gov/study/NCT02723994","created_at":"2021-01-18T13:19:54.627Z","updated_at":"2024-07-02T16:35:23.552Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02723994 - AALL1521","lead_sponsor":"Incyte Corporation","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion","tags":["JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-12"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"69cb4874-6acd-473c-a768-125ee02be69d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06159816","created_at":"2023-12-09T13:25:04.714Z","updated_at":"2024-07-02T16:35:26.773Z","phase":"","brief_title":"PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES","source_id_and_acronym":"NCT06159816","lead_sponsor":"AUSL Romagna Rimini","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-12-07"},{"id":"434adfdd-8113-4766-9f0b-9b5c20203527","acronym":"","url":"https://clinicaltrials.gov/study/NCT03571321","created_at":"2021-01-18T17:34:27.181Z","updated_at":"2024-07-02T16:35:27.762Z","phase":"Phase 1","brief_title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03571321","lead_sponsor":"University of Chicago","biomarkers":" JAK2 • CRLF2 • IL7R • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion","tags":["JAK2 • CRLF2 • IL7R • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/05/2027","study_completion_date":" 09/05/2027","last_update_posted":"2023-11-29"}]